FDA Proposed Master Protocol For Zykadia Trial; Novartis Had Other Plans
This article was originally published in Pharmaceutical Approvals Monthly
FDA floated the idea of using a master protocol to provide the required confirmation of clinical benefit for ceritinib’s accelerated approval, but Novartis chose to rely on two traditional Phase III trials, either of which could meet the regulatory standard.
You may also be interested in...
Tropical diseases were not neglected by the Center for Biologics Evaluation and Research in 2019, producing three novel vaccines (which earned three priority review vouchers) and tilting the approval class toward expedited review programs.
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
Pink Sheet infographic illustrates new drug approval trends and highlights from the past decade at the US FDA.